Sildenafil as a Candidate Drug for Alzheimer’s Disease: Real-World Patient Data Observation and Mechanistic Observations from Patient-Induced Pluripotent Stem Cell-Derived Neurons
Dhruv Gohel(Maharaja Sayajirao University of Baroda), Feixiong Cheng(Cleveland Clinic Lerner College of Medicine), Andrew A. Pieper(Cornell University), Pengyue Zhang(Indiana University Health), Lang Li(Sun Yat-sen University), Yi‐Chen Li(Harbin Medical University), Chien‐Wei Chiang(The Ohio State University), Amit Gupta(Cleveland Clinic Lerner College of Medicine), Yuan Hou(Cleveland Clinic Lerner College of Medicine), Jeffrey L. Cummings(University of California, Los Angeles)
Cited by 19
Related Papers
Common variants at MS4A4/MS4A6E, CD2AP, CD33 and EPHA1 are associated with late-onset Alzheimer's disease
|Nature Genetics|2011|2k
Preclinical Alzheimer's disease: Definition, natural history, and diagnostic criteria
|Alzheimer s & Dementia|2016|1.9k
Alzheimer's disease
|Nature Reviews Disease Primers|2015|1.8k
Positron Emission Tomography in Evaluation of Dementia
|JAMA|2001|952
A randomized, double-blind, phase 2b proof-of-concept clinical trial in early Alzheimer’s disease with lecanemab, an anti-Aβ protofibril antibody
|Alzheimer s Research & Therapy|2021|818